Literature DB >> 23683769

Pathogenesis of Morquio A syndrome: an autopsied case reveals systemic storage disorder.

Eriko Yasuda1, Kazunari Fushimi, Yasuyuki Suzuki, Katsuji Shimizu, Tsuyoshi Takami, Jozef Zustin, Pravin Patel, Kristen Ruhnke, Tsutomu Shimada, Bobbie Boyce, Terry Kokas, Carol Barone, Mary Theroux, William Mackenzie, Barbara Nagel, Jan S Ryerse, Kenji E Orii, Hiroki Iida, Tadao Orii, Shunji Tomatsu.   

Abstract

Mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome) is a lysosomal storage disorder caused by deficiency of N-acetylgalactosamine-6-sulfate sulfatase, which results in systemic accumulation of glycosaminoglycans (GAGs), keratan sulfate and chondroitin-6-sulfate. Accumulation of these GAGs causes characteristic features as disproportionate dwarfism associated with skeletal deformities, genu valgum, pigeon chest, joint laxity, and kyphoscoliosis. However, the pathological mechanism of systemic skeletal dysplasia and involvement of other tissues remain unanswered in the paucity of availability of an autopsied case and successive systemic analyses of multiple tissues. We report here a 20-year-old male autopsied case with MPS IVA, who developed characteristic skeletal features by the age of 1.5 years and died of acute respiratory distress syndrome five days later after occipito-C1-C2 cervical fusion. We pathohistologically analyzed postmortem tissues including trachea, lung, thyroid, humerus, aorta, heart, liver, spleen, kidney, testes, bone marrow, and lumbar vertebrae. The postmortem tissues relevant with clinical findings demonstrated 1) systemic storage materials in multiple tissues beyond cartilage, 2) severely vacuolated and ballooned chondrocytes in trachea, humerus, vertebrae, and thyroid cartilage with disorganized extracellular matrix and poor ossification, 3) appearance of foam cells and macrophages in lung, aorta, heart valves, heart muscle, trachea, visceral organs, and bone marrow, and 4) storage of chondrotin-6-sulfate in aorta. This is the first autopsied case with MPS IVA whose multiple tissues have been analyzed pathohistologically and these pathological findings should provide a new insight into pathogenesis of MPS IVA.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23683769     DOI: 10.1016/j.ymgme.2013.04.009

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  44 in total

1.  Chondroitin 6-Sulfate as a Novel Biomarker for Mucopolysaccharidosis IVA and VII.

Authors:  Tsutomu Shimada; Shunji Tomatsu; Eriko Yasuda; Robert W Mason; William G Mackenzie; Yuniko Shibata; Francyne Kubaski; Roberto Giugliani; Seiji Yamaguchi; Yasuyuki Suzuki; Kenji Orii; Tadao Orii
Journal:  JIMD Rep       Date:  2014-05-22

2.  Paraplegia after epidural-general anesthesia in a Morquio patient with moderate thoracic spinal stenosis.

Authors:  John C Drummond; Elliot J Krane; Shunji Tomatsu; Mary C Theroux; Roland R Lee
Journal:  Can J Anaesth       Date:  2014-10-17       Impact factor: 5.063

Review 3.  Mucopolysaccharidosis IVA and glycosaminoglycans.

Authors:  Shaukat Khan; Carlos J Alméciga-Díaz; Kazuki Sawamoto; William G Mackenzie; Mary C Theroux; Christian Pizarro; Robert W Mason; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-11-29       Impact factor: 4.797

4.  Outcomes from 18 years of cervical spine surgery in MPS IVA: a single centre's experience.

Authors:  A Broomfield; K Zuberi; J Mercer; G Moss; N Finnegan; P Hensman; R Walker; S Bukhari; N B Wright; F Stewart; S A Jones; R Ramirez
Journal:  Childs Nerv Syst       Date:  2018-06-26       Impact factor: 1.475

5.  Enzyme replacement therapy in newborn mucopolysaccharidosis IVA mice: early treatment rescues bone lesions?

Authors:  Shunji Tomatsu; Adriana M Montaño; Hirotaka Oikawa; Vu Chi Dung; Amiko Hashimoto; Toshihiro Oguma; Monica L Gutiérrez; Tatsuo Takahashi; Tsutomu Shimada; Tadao Orii; William S Sly
Journal:  Mol Genet Metab       Date:  2014-06-04       Impact factor: 4.797

6.  Aortic root dilatation in patients with mucopolysaccharidoses and the impact of enzyme replacement therapy.

Authors:  Fabiano de Oliveira Poswar; Carolina Fischinger Moura de Souza; Roberto Giugliani; Guilherme Baldo
Journal:  Heart Vessels       Date:  2018-08-22       Impact factor: 2.037

7.  Widespread Vasculopathy in a Patient with Morquio A Syndrome.

Authors:  Adam W Powell; Michael D Taylor; T Andrew Burrow; Robert J Hopkin; Carlos E Prada; John L Jefferies
Journal:  Tex Heart Inst J       Date:  2017-12-19

8.  Activity of daily living for Morquio A syndrome.

Authors:  Eriko Yasuda; Yasuyuki Suzuki; Tsutomu Shimada; Kazuki Sawamoto; William G Mackenzie; Mary C Theroux; Christian Pizarro; Li Xie; Freeman Miller; Tariq Rahman; Heidi H Kecskemethy; Kyoko Nagao; Thierry Morlet; Thomas H Shaffer; Yasutsugu Chinen; Hiromasa Yabe; Akemi Tanaka; Haruo Shintaku; Kenji E Orii; Koji O Orii; Robert W Mason; Adriana M Montaño; Toshiyuki Fukao; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-04-25       Impact factor: 4.797

9.  Obstructive airway in Morquio A syndrome, the past, the present and the future.

Authors:  Shunji Tomatsu; Lauren W Averill; Kazuki Sawamoto; William G Mackenzie; Michael B Bober; Christian Pizarro; Christopher J Goff; Li Xie; Tadao Orii; Mary Theroux
Journal:  Mol Genet Metab       Date:  2015-09-21       Impact factor: 4.797

Review 10.  Therapies for the bone in mucopolysaccharidoses.

Authors:  Shunji Tomatsu; Carlos J Alméciga-Díaz; Adriana M Montaño; Hiromasa Yabe; Akemi Tanaka; Vu Chi Dung; Roberto Giugliani; Francyne Kubaski; Robert W Mason; Eriko Yasuda; Kazuki Sawamoto; William Mackenzie; Yasuyuki Suzuki; Kenji E Orii; Luis A Barrera; William S Sly; Tadao Orii
Journal:  Mol Genet Metab       Date:  2014-12-09       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.